Department of Biomedical Sciences and Human Oncology, Unit of General Pathology, University of Bari Aldo Moro, I‑70124 Bari, Italy.
Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari Aldo Moro, I‑70124 Bari, Italy.
Oncol Rep. 2019 May;41(5):2615-2624. doi: 10.3892/or.2019.7082. Epub 2019 Mar 21.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most commonly diagnosed cancer worldwide. It has poor clinical outcome due to intrinsic or acquired drug resistance. Deregulation of both apoptosis and autophagy contributes to chemotherapy resistance and disease progression. A new member of the inhibitors of apoptosis protein (IAP) family, namely survivin, is selectively overexpressed in tumors, including HNSCC, but not in normal tissues. Thus, it is considered a tumor biomarker. Here, we reviewed survivin expression and function in tumor progression focusing on its nodal role in the regulation of cell apoptosis and autophagy. Based on literature data, survivin targeting may be envisaged as a novel therapeutic strategy.
头颈部鳞状细胞癌（HNSCC）是全球第六种最常见的癌症。由于内在或获得性药物耐药性，其临床预后较差。凋亡和自噬的失调导致化疗耐药和疾病进展。凋亡抑制蛋白（IAP）家族的新成员 survivin 选择性地在肿瘤中过度表达，包括 HNSCC，但在正常组织中不表达。因此，它被认为是一种肿瘤标志物。在这里，我们综述了 survivin 在肿瘤进展中的表达和功能，重点讨论了其在调节细胞凋亡和自噬中的节点作用。基于文献数据，survivin 的靶向治疗可能是一种新的治疗策略。
